Related Experiment Video
Updated: Aug 5, 2026
07:51
Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
Published on: September 22, 2011
Renal vasodepressor mechanisms: the medullipin system
1Department of Pathology, University of Tennessee, Memphis 38163.
Summary
Medullipin, a renal vasodepressor hormone, regulates blood pressure. Its deficiency contributes to hypertension, while its secretion is influenced by renal artery pressure.
Area of Science:
- Nephrology
- Cardiovascular Physiology
- Endocrinology
Background:
- Medullipin I is a renomedullary vasodepressor hormone produced by renal papilla interstitial cells.
- It is converted to active medullipin II in the liver, acting as a vasodilator and opposing angiotensin II.
- Medullipin deficiency is linked to hypertensive states.
Purpose of the Study:
- To investigate the role of medullipin in blood pressure regulation.
- To understand the causes and implications of medullipin deficiency in hypertension.
- To explore the regulation of medullipin secretion by renal perfusion pressure.
Main Methods:
- Review of existing literature on medullipin, hypertension, and renal physiology.
- Analysis of the relationship between medullipin, angiotensin II, and sympathetic tone.
- Examination of factors affecting medullipin secretion and conversion.
Main Results:
- Medullipin II acts as a vasodilator, suppresses sympathetic tone, and promotes diuresis/natriuresis.
- Causes of medullipin deficiency include loss or damage to renomedullary interstitial cells and cellular dysfunction.
- Renal artery perfusion pressure is a key regulator of medullipin I secretion, inversely to renin secretion.
Conclusions:
- Medullipin plays a crucial role in blood pressure homeostasis.
- Dysfunction or deficiency of medullipin contributes to hypertension.
- Understanding medullipin regulation offers potential therapeutic targets for hypertensive disorders.
More Related Videos
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:18Neural Regulation of Blood Pressure
The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
01:17Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...